‘Dutch taxpayers money wasted!’ Nexit fury as EU buys 405m doses of failed German jab

CureVac 'failed to meet efficacy target' reveals host

When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. Our Privacy Notice explains more about how we use your data, and your rights. You can unsubscribe at any time.

Campaigners at the Nexit Denktank, fighting for the Netherlands to leave the EU, blasted the Commission at the news the German vaccine CureVac failed to prove effective. The Commission had purchased 405 million doses of the jab for member states in the bloc, a move branded a “waste” of taxpayers money, according to the furious campaigners.

They said: “The German vaccine is only 47 percent effective.

“After months of scaremongering about Britain’s AstraZeneca and Russia’s Sputnik V, this is the best that can be produced in Germany…

“The EU has bought 405 million of these vaccines.

“Dutch tax money wasted.


Citing former MEP Martin Daubney of the Brexit Party, they continued: “Remainers thought that without the EU we would be isolated and weak.

“Until now, only the eurosceptics had paid attention, but now everyone can see what the EU really is like.

“The UK’s vaccination policy is the best ad for Brexit!”

German biotech firm CureVac saw billions of euros wiped from its market value on Thursday after its COVID-19 vaccine proved only 47 percent effective in an initial trial read-out, denting investor confidence in its ability to take on rival shots.

The disappointing efficacy of its vaccine, CVnCoV, emerged from an interim analysis in a study of about 40,000 volunteers in Europe and Latin America, with CureVac saying on Wednesday that new variants had proved a headwind.

READ MORE: Thousands of Europeans facing losing benefits in UK

CureVac shares listed in Frankfurt and New York fell more than 50 percent in early trading in those markets and were down 43 percent at 2:51pm on Thursday, their lowest in more than seven months, erasing more than 6 billion euros from the company’s market value.

Late-stage trials of BioNTech/Pfizer and Moderna vaccines, which like CureVac’s are based on mRNA technology, had efficacy rates of well above 90 percent but took place when the original version of the coronavirus was dominant.

Data on their products have, however, so far suggested only somewhat weaker protection against new variants.

CureVac, which had registered 134 infections overall for the initial analysis, said it expected to publish final results based on more than 200 cases in two to three weeks’ time.

Irish fishermen to storm Dublin in angry protest against EU [ANALYSIS]
SNP could have rugged pulled from under them – Boris handed masterplan [INSIGHT]
Brexit LIVE: Emmanuel Macron plots to steal UK business [LIVE BLOG]

Sufficient additional infections had already occurred among participants but had yet to be vetted for inclusion in the final analysis, it added.

Public health representatives across the globe are pushing for a fast deployment of available vaccines to counter highly contagious mutations of COVID-19 such as the Delta variant that first emerged in India.

CureVac’s readout was in stark contrast with results announced by Novavax this week, showing that its experimental COVID-19 vaccine was more than 90 percent effective, including against a variety of concerning variants of the coronavirus in a U.S.-based clinical trial.

Yet, CureVac’s efficacy rate was similar to Sinovac’s vaccine which the World Health Organisation said this month was 51 percent effective in preventing symptomatic disease, taking the Chinese shot one step closer to be deployed in low and middle-income countries under the COVAX platform.

CureVac CEO Franz-Werner Haas told Reuters the company still planned to apply for approval from the European Medicines Agency (EMA), provided the shot clears the formal hurdle of 50 percent efficacy.

However the EMA said on Thursday it would not impose a 50 percent efficacy threshold for vaccines, adding full trial data was necessary for it to make a sound assessment on the benefits and risks of a shot.

Under CureVac’s only major supply deal for the product tested in the trial, the European Union secured up to 405 million doses of the vaccine in November, of which 180 million are optional.

In a bet on CureVac’s technology, Britain placed a conditional 50 million dose order in February on yet-to-be-developed vaccines that build on the product tested in the trial.

After the interim results, the European Commission said it would need to wait for final results and the assessment of the EU drugs regulator before taking any steps, a spokeswoman for the EU executive told a news conference on Thursday.

Source: Read Full Article